anrotenib
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04229849)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
FLT1 inhibitor
KDR inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
FLT4 inhibitor
PDGFRA inhibitor
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
KIT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06585644 | Phase 2 | Oct 1, 2024 | Huazhong University of Science and Technology |
| NCT06886347 | Phase 1 | Jul 7, 2023 | Chinese Academy of Medical Sciences |
| NCT05685550 | Phase 2 | Jan 28, 2023 | Tianjin Medical University |
| NCT05608785 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2023 | Henan Medical University |
| NCT05683704 | Phase 2 | Sep 1, 2022 | Tianjin Medical University |
| NCT06611657 | Phase 2 | Aug 20, 2021 | Chinese Academy of Medical Sciences |
| NCT04229849 | Phase 2 | Jan 31, 2020 | Henan Medical University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Henan Medical University | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Tianjin Medical University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1